Dashboard
Manage Tickers

GILD GILEAD SCIENCES, INC.

Nasdaq gilead.com


$ 127.90 $ 0.00 (0 %)    

Thursday, 20-Nov-2025 08:09:42 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 610.59 $ 0.00 (0 %)
DIA $ 464.87 $ 0.00 (0 %)
SPY $ 671.23 $ 0.00 (0 %)
TLT $ 88.85 $ 0.00 (0 %)
GLD $ 375.93 $ 0.00 (0 %)
$ 128.07
$ 127.09
$ 127.80 x 1
$ 128.00 x 2
-- - --
$ 85.23 - $ 128.10
6,881,858
na
158.89B
$ 0.48
$ 19.59
TBD
na
na ($ 0.02)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-07-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-07-2025 03-31-2025 10-Q
4 02-28-2025 01-01-1970 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 02-23-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-04-2023 06-30-2023 10-Q
11 05-03-2023 03-31-2023 10-Q
12 02-22-2023 12-31-2022 10-K
13 11-02-2022 09-30-2022 10-Q
14 08-08-2022 06-30-2022 10-Q
15 05-04-2022 03-31-2022 10-Q
16 02-23-2022 12-31-2021 10-K
17 11-03-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 02-25-2021 12-31-2020 10-K
21 11-04-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-06-2020 03-31-2020 10-Q
24 02-25-2020 12-31-2019 10-K
25 11-05-2019 09-30-2019 10-Q
26 08-06-2019 06-30-2019 10-Q
27 05-08-2019 03-31-2019 10-Q
28 02-26-2019 12-31-2018 10-K
29 11-06-2018 09-30-2018 10-Q
30 08-06-2018 06-30-2018 10-Q
31 05-09-2018 03-31-2018 10-Q
32 02-27-2018 12-31-2017 10-K
33 11-07-2017 09-30-2017 10-Q
34 08-07-2017 06-30-2017 10-Q
35 05-10-2017 03-31-2017 10-Q
36 02-27-2017 12-31-2016 10-K
37 11-07-2016 09-30-2016 10-Q
38 08-05-2016 06-30-2016 10-Q
39 05-06-2016 03-31-2016 10-Q
40 02-24-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

mercks-investigational-two-drug-regime-matches-gileads-three-drug-tablet-for-hiv-treatment
Merck's Investigational Two-Drug Regime Ma...
11/19/2025 18:23:40

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application ...

gilead-sciences-delivers-first-shipments-of-lenacapavir-twice-yearly-injectable-hiv-1-capsid-inhibitor--for-the-prevention-of-hiv-as-pre-exposure-prophylaxis-to-eswatini-and-zambia
Gilead Sciences Delivers First Shipments O...
11/18/2025 10:45:21

gilead-sciencess-options-a-look-at-what-the-big-money-is-thinking
Gilead Sciences's Options: A Look at What ...
11/17/2025 20:02:43

gileads-one-pill-hiv-treatment-shows-promise-in-late-stage-trial
Gilead's One-Pill HIV Treatment Shows Prom...
11/13/2025 18:55:41

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy a...

needham-maintains-buy-on-gilead-sciences-raises-price-target-to-140
Needham Maintains Buy on Gilead Sciences, ...
11/13/2025 18:11:32

Needham analyst Joseph Stringer maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $133 to ...

this-gilead-sciences-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday
This Gilead Sciences Analyst Begins Covera...
11/13/2025 13:45:16

gilead-sciences-releases-topline-results-from-phase-3-artistry-1-trial-showing-that-once-daily-single-tablet-regimen-of-bictegravir-75-mglenacapavir-50-mg-is-non-inferior-to-multi-tablet-antiretroviral-regimens-in-virologically-suppressed-adults-with-hiv
Gilead Sciences Releases Topline Results F...
11/13/2025 13:43:09

Gilead Sciences, Inc. (NASDAQ:GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The open-label ...

scotiabank-initiates-coverage-on-gilead-sciences-with-sector-outperform-rating-announces-price-target-of-140
Scotiabank Initiates Coverage On Gilead Sc...
11/13/2025 12:24:06

Scotiabank analyst Louis Chen initiates coverage on Gilead Sciences (NASDAQ:GILD) with a Sector Outperform rating and announ...

gilead-cfo-says-medicare-reform-is-about-900m-headwind-for-hiv-business-12b-headwind-for-business-overall
Gilead CFO Says Medicare Reform Is About $...
11/10/2025 16:12:57

- Reuters Citing Conf Call

gilead-cfo-says-hiv-business-is-now-projected-to-grow-5-this-year
Gilead CFO Says HIV Business Is Now Projec...
11/10/2025 16:11:23

- Reuters Citing Conf Call

in-oct-gilead-sciences-reached-settlement-with-a-tax-authority-related-to-a-prior-year-legal-entity-restructuring--sees-450m-of-income-tax-benefit-and-a-corresponding-530m-reduction-in-unrecognized-tax-benefits-in-quarter-ending-dec-31
In Oct, Gilead Sciences Reached Settlement...
11/07/2025 21:26:50

-SEC Filing

gileads-trodelvy-misses-main-goal-in-breast-cancer-study-but-shows-early-survival-trend
Gilead's Trodelvy Misses Main Goal In Brea...
11/07/2025 15:10:32

Gilead's Trodelvy missed a key goal in breast cancer, while Livdelzi showed durable efficacy and safety in long-term liver ...

gilead-says-phase-3-ascent-07-study-of-trodelvy-did-not-meet-primary-endpoint-of-progression-free-survival
Gilead Says Phase 3 ASCENT-07 Study Of Tro...
11/07/2025 13:31:38

gilead-announces-long-term-data-showing-sustained-efficacy-in-primary-biliary-cholangitis
Gilead Announces Long-Term Data Showing Su...
11/07/2025 13:04:22

Core News & Articles
10 Health Care Stocks Whale Activity In To...
11/05/2025 17:35:20

truist-securities-reiterates-buy-on-gilead-sciences-raises-price-target-to-145
Truist Securities Reiterates Buy on Gilead...
11/03/2025 15:23:56

Truist Securities analyst Asthika Goonewardene reiterates Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price targ...

gilead-sciences-and-kite-to-present-21-abstracts-including-5-oral-presentations-showcasing-kites-continued-progress-in-transforming-blood-cancer-care-and-expanding-reach-and-impact-of-car-t-cell-therapy-at-ash-2025
Gilead Sciences And Kite To Present 21 Abs...
11/03/2025 14:21:20

– Updated Results from Phase 2 Pivotal iMMagine-1 Study of Anito-cel for Relapsed/Refractory Multiple Myeloma to be Presented O...

wells-fargo-maintains-overweight-on-gilead-sciences-raises-price-target-to-145
Wells Fargo Maintains Overweight on Gilead...
10/31/2025 21:12:51

Wells Fargo analyst Mohit Bansal maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from ...

jp-morgan-maintains-overweight-on-gilead-sciences-raises-price-target-to-150
JP Morgan Maintains Overweight on Gilead S...
10/31/2025 18:36:06

JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $1...

gileads-hiv-drugs-power-earnings-beat-company-eyes-multiple-launches-by-2026
Gilead's HIV Drugs Power Earnings Beat, Co...
10/31/2025 17:41:12

Gilead beats estimates, raises 2025 guidance, driven by strong HIV and liver drug sales and multiple launches planned for 2026.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION